Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib Plus Darolutamide in Metastatic Castration-Resistant Prostate Cancer
NCT05999968Phase 1Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2024
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of abemaciclib and darolutamide in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration at 32 months. Started Jan 2024; status: terminated.
02
Drugs
abemaciclibdarolutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05999968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05999968.